Core Points - A class action has been filed against Flywire Corporation on behalf of investors who acquired its securities between February 28, 2024, and February 25, 2025 [1] - Allegations include that Flywire misled investors about the sustainability of its revenue growth and downplayed the negative impact of permit and visa-related restrictions on its business [2] - On February 25, 2025, Flywire announced disappointing financial results for Q4 and FY 2024, expecting revenue declines of over 30% year-over-year in Canadian and Australian markets due to policy changes and new visa rules [3] - Following the announcement, Flywire's stock price dropped by $6.59, or 37.36%, closing at $11.05 per share on February 26, 2025 [3] Company and Industry Summary - Flywire operates as a payments-enablement and software company both in the U.S. and internationally [1] - The company is facing scrutiny regarding its revenue growth claims and the effects of regulatory changes on its operations [2] - The recent financial disclosures have led to analyst downgrades and price target cuts, indicating a negative outlook for the company's performance [3]

Group 1 - A class action has been filed on behalf of investors who purchased Sable Offshore Corp. (NYSE: SOC) securities between May 19, 2025, and June 3, 2025, and/or traceable to the Company's May 21, 2025 secondary public offering [1] - The allegations state that Sable Offshore Corp. misled investors by claiming that oil production had restarted off the coast of California when it had not, leading to investor losses when the truth was revealed [2] - Shareholders interested in serving as lead plaintiff must submit their papers by September 26, 2025, and can remain absent class members if they choose not to participate [3] Group 2 - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses for representation [4] - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]

Core Viewpoint - A class action lawsuit has been filed against Charter Communications, Inc. for allegedly misleading investors about its business prospects, particularly regarding the impact of the Affordable Connectivity Program's end on customer declines and revenue [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Charter failed to disclose the material impact of the Affordable Connectivity Program (ACP) ending, which affected Internet customer declines and revenue [2]. - It is alleged that Charter's operational strategies were not sufficient to mitigate the negative effects of the ACP ending, leading to greater risks to business plans and earnings growth than reported [2]. - The company reportedly provided overly optimistic statements about its operational execution and long-term EBITDA growth without a reasonable basis [2]. Group 2: Financial Performance - Charter reported an EBITDA of $5.7 billion for Q2 2025, indicating a year-over-year growth of 0.5%. However, this growth was attributed to a one-time benefit of $45 million in "other revenue" [3]. - Excluding this one-time benefit, EBITDA would have missed consensus estimates by 2.4% and shown a decline of 0.3% year-over-year [3]. - Following the financial results announcement, Charter's stock price dropped by $70.25, or over 18%, closing at $309.75 per share on July 25, 2025 [3].

Core Viewpoint - A class action has been filed against Unicycive Therapeutics, Inc. for allegedly misleading investors regarding the readiness of its drug application and compliance with FDA manufacturing requirements [1][2]. Group 1: Allegations and Legal Action - Robbins LLP is investigating allegations that Unicycive Therapeutics misled investors about the prospects of its New Drug Application (NDA) for oxylanthanum carbonate (OLC) [2]. - The complaint claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [2]. - Shareholders are encouraged to participate in the class action and can contact Robbins LLP before the October 14, 2025 deadline to serve as lead plaintiff [4]. Group 2: Stock Performance and FDA Actions - On June 10, 2025, Unicycive announced that the FDA identified deficiencies in cGMP compliance at a third-party manufacturing vendor, leading to a stock price drop of over 40% [3]. - Following the FDA's issuance of a Complete Response Letter for the OLC NDA on June 30, 2025, Unicycive's stock fell nearly 30%, closing at $4.77 per share [3].

Core Viewpoint - Robbins LLP has filed a class action on behalf of investors who acquired Fiserv, Inc. common stock during a specified period, alleging that the company misled investors regarding the growth prospects of its Clover platform [1][2]. Allegations - Fiserv allegedly forced Payeezy merchants to migrate to its Clover platform due to cost issues and problems with Payeezy, which temporarily boosted Clover's revenue and GPV growth, concealing a slowdown in new merchant business [2]. - Following the forced conversions, many former Payeezy merchants switched to competing solutions due to Clover's high pricing and inadequate customer service, leading to a significant slowdown in Clover's GPV growth and unsustainable revenue growth [2]. - The positive statements made by Fiserv regarding Clover's growth strategies and business prospects during the class period were claimed to be materially false and misleading [2]. Impact on Stock - The truth regarding these issues was revealed through a series of disclosures, resulting in a decline in Fiserv, Inc.'s stock and harming investors [3]. Next Steps for Shareholders - Shareholders interested in serving as lead plaintiffs must file their motions by September 22, 2025, while those who choose not to participate can remain as absent class members [4]. Company Background - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002, operating on a contingency fee basis where shareholders pay no fees or expenses [5].

Group 1 - A class action has been filed against Centene Corporation on behalf of investors who acquired its securities between December 12, 2024, and June 30, 2025 [1] - Allegations state that Centene misled investors about its business prospects, creating a false impression of reliable revenue outlook and growth while actual enrollment rates and morbidity were lower than expected [2] - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that market growth across 22 states was lower than anticipated, leading to a reduction in guidance to approximately $1.8 billion and an adjusted diluted EPS of $2.75 [3] Group 2 - Following the announcement on July 1, 2025, Centene's stock price dropped from $56.65 to $44.78 per share, a decline of over 40% [3] - Shareholders are encouraged to participate in the class action, with options to serve as lead plaintiff or remain an absent class member [4] - Robbins LLP has been dedicated to shareholder rights litigation since 2002, focusing on helping shareholders recover losses and improve corporate governance [5]

Group 1 - A class action has been filed on behalf of investors who purchased Sable Offshore Corp. (NYSE: SOC) securities between May 19, 2025, and June 3, 2025, related to the company's secondary public offering on May 21, 2025 [1][2] - The allegations state that Sable Offshore Corp. misled investors by claiming that oil production had restarted off the coast of California when it had not, leading to investor losses when the truth was revealed [2] - Shareholders interested in serving as lead plaintiff must submit their papers by September 26, 2025, and can choose to remain absent class members if they do not wish to participate [3] Group 2 - Robbins LLP is a recognized leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [4]

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Lockheed Martin Corporation securities between January 23, 2024, and July 21, 2025, alleging that the company misled investors regarding its business prospects [1][2]. Allegations - The complaint states that Lockheed Martin failed to disclose several critical issues, including: - Inefficient internal controls related to risk-adjusted contracts and profit booking rates [2] - Lack of effective procedures for comprehensive reviews of program requirements and risks [2] - Overstatement of its ability to meet contract commitments regarding cost, quality, and schedule [2] - Likelihood of reporting significant losses as a result of these issues [2] Financial Impact - On July 22, 2025, Lockheed Martin disclosed an additional $1.6 billion in pre-tax losses on classified programs, which included: - $950 million in losses from the Aeronautics Classified program - $570 million in losses from the Canadian Maritime Helicopter Program - $95 million charge related to the Turkish Utility Helicopter Program - Following this announcement, the company's share price dropped by $49.79, or over 10%, closing at $410.74 [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers by September 26, 2025, but participation is not required to be eligible for recovery [4].

Core Viewpoint - A class action has been filed against CTO Realty Growth, Inc. for allegedly misleading investors about its financial health and sustainability of dividends during the specified period [1][2]. Allegations - The complaint states that CTO Realty Growth, Inc. did not disclose that its dividends were less sustainable than claimed, used deceptive practices to inflate its Adjusted Funds from Operations (AFFO), and overstated its business and financial prospects [2]. - Wolfpack Research's report accused CTO of not generating sufficient cash to cover its recurring capital expenditures and dividends since its conversion to a REIT in 2021, relying on a 70% increase in shares outstanding to cover a $38 million dividend shortfall from 2021 to 2024, and employing a manipulative definition of AFFO [3]. Financial Condition - The report highlighted that CTO had only $8.4 million in cash while facing quarterly dividends of $14 million and average recurring capital expenditures of $5.7 million, along with an additional $12 million in planned capital expenditures [3].

Core Viewpoint - Spectrum Pharmaceuticals, Inc. is facing a class action lawsuit alleging false or misleading statements regarding its clinical trial for the drug poziotinib, which is intended for lung cancer treatment [2]. Group 1: Company Overview - Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies [1]. Group 2: Legal Proceedings - The class action lawsuit pertains to the Pinnacle Study, a clinical trial involving the drug poziotinib [2]. - The Lead Plaintiff appointment process has reopened, allowing shareholders who purchased shares between March 17, 2022, and September 22, 2022, to file their papers by September 24, 2025 [3]. Group 3: Shareholder Information - Shareholders do not need to participate in the case to be eligible for recovery [3]. - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses [4].